Federal Contractor Profile
Mapp Biopharmaceutical, INC.
Federal contracting record: $609M obligated across 21 awards from 2 agencies, FY 2016–2026.
$609M
Total Obligated
21
Award Records
2
Agencies Served
7
NAICS Codes
Company Profile
Parent UEI (Unique Entity Identifier)
M9V9QTHR1H28
CAGE Code
417U0
Address
6160 LUSK BLVD STE 105, SAN DIEGO, CA, 921212740
First Federal Award
Nov 24, 2015
Most Recent Award
Sep 18, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$557M
98.8% of total obligations
- Department of Defense$6.8M
1.2% of total obligations
Top NAICS Activity
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Sep 18, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $322K |
| Sep 14, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. | $44M |
| Aug 12, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS | $2.6M |
| Jul 27, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $33M |
| Jul 8, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $3.2M |
| Sep 16, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | 325413 | HUMAN-DERIVED MONOCLONAL ANTIBODIES AND RECOMBINANT ANTIGENS | $61K |
| Jul 11, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $50M |
| Jun 5, 2025 | Department of DefenseARMY MED RES ACQ ACTIVITY | 325413 | ANTIBODY & ANTIGEN SUPPLY | $111K |
| May 28, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS | $43K |
| Jun 24, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | $109K |
| Mar 19, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS | $3.0M |
| Sep 22, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $8.6M |
| Aug 7, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. | $13M |
| Jun 29, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | $718K |
| May 3, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | $1.5M |
| Apr 19, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. | $20M |
| Mar 1, 2023 | Department of DefenseW4PZ USA MED RSCH ACQUIS ACT | 541380 | BASE YEAR FOR MACV CONTRACT GENERATES MACV IGG2 | $298K |
| Dec 22, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $17M |
| Dec 7, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541715 | IGF::OT::IGF | $868K |
| Dec 5, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | MAPP 2019 CONTRACT | $720K |
| Sep 28, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. | $78M |
| Sep 27, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | $110M |
| Sep 21, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541720 | MAPP EAP - IGF::CL::IGF FOR OTHER FUNCTIONSEXPANDED ACCESS PROTOCOL FOR ZMAPP | $2.4M → |
| Aug 15, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE | $4.5M |
| Jun 22, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF | $182K → |
Want to win work like Mapp Biopharmaceutical, INC.?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.